CFDA Granted Approval of Phase I-III Clinical Trials for Sirotinib (XZP - 5491)
2016-08-26 15:45:36 Author:admin
       Clinical Trials of Sirotinib (XZP - 5491) by CFDA with the Approval Numbers of 2016L06493 and 2016L06497.

       As a pan-Her inhibitor, Sirotinib is the second innovative oncology drug developed by Xuanzhu Pharma. Our comprehensive preclinical studies demonstrated that Sirotinib has excellent efficacies on a broad range of cancers and with unique pharmacokinetic properties which can effectively penetrate the blood brain barrier.         

       The approval of Sirotinib for the phase I-III clinical trials represents another milestone in the SiHuan/ XuanZhu’s new drug discovery history. We enter into a new clinical stage of the development process, and we have many works remaining before us. It is still an urgent task for us to accelerate the clinical development, and to launch the drug product in the China market as soon as possible.

Email | Terms of Use | Contact us

2014版權?軒竹醫藥科技有限公司保留所有權利 魯ICP備09030169號

圣盛湖北公安晃晃麻将 四川麻将怎么打 温州麻将打牌顺序 新疆体彩11选5走势图 挂机赚app是真的吗 股票历史行情查询 华人策略博彩论坛 足球直播西甲 网络赚 论坛 重庆麻将机维修 幸运飞艇冠亚单最高倍率平台